2,4-diketone Pyrimidine Or Derivative (e.g., Uracil, Etc.) Patents (Class 514/50)
-
Publication number: 20100197629Abstract: A pharmaceutical solution suitable for oral administration comprising ?-L-thymidine/2?-deoxy-L-thymidine (telbivudine), a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents, a preservative system, and a buffer system suitable to allow both drug stability and preservation.Type: ApplicationFiled: July 10, 2008Publication date: August 5, 2010Applicant: NOVARTIS AGInventor: Nabila Sekkat
-
Publication number: 20100189687Abstract: The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.Type: ApplicationFiled: February 22, 2008Publication date: July 29, 2010Applicant: GILEAD SCIENCES, INC.Inventors: Manoj C. Desai, Allen Y. Hong, Hon Chung Hui, Hongtao Liu, Randall W. Vivian, Lianhong Xu
-
Publication number: 20100189771Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.Type: ApplicationFiled: October 25, 2006Publication date: July 29, 2010Inventors: Lawrence Mayer, Christine Swenson, Andrew Janoff, John Redman
-
Publication number: 20100184717Abstract: The invention relates generally to treatment of muscle pain and/or fatigue and to methods of treatment of side effects of statin therapy which involve the administration of uridine, biological precursors or derivatives or uridine or salts, esters, tautomers or analogues thereof, which are collectively referred to as uridine related compounds. The invention is also directed to compositions, uses and combination packs or kits related to the treatment method.Type: ApplicationFiled: January 22, 2010Publication date: July 22, 2010Applicant: MAGRAL PTY LTD.Inventor: Anthony William Linnane
-
Patent number: 7759322Abstract: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5?-triphosphate (UTP), dinucleotides, cytidine 5?-triphosphate (CTP), adenosine 5?-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.Type: GrantFiled: June 20, 2007Date of Patent: July 20, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Karla M. Jacobus, William Pendergast, Janet L. Rideout
-
Publication number: 20100173863Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 27, 2009Publication date: July 8, 2010Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
-
Publication number: 20100166798Abstract: The method includes the steps of cleansing of the scalp sufficiently to remove material which would otherwise block antiviral medication from reaching hair follicles, heating the scalp to increase the absorption of the antiviral medication and applying the antiviral medication to the scalp in effective amount to suppress viral replication or viral activation present in the nerves leading to the scalp.Type: ApplicationFiled: November 4, 2009Publication date: July 1, 2010Applicant: Pacific Bioscience Laboratories, Inc.Inventor: Robert E. Akridge
-
Publication number: 20100168052Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.Type: ApplicationFiled: December 28, 2009Publication date: July 1, 2010Applicants: Pharmasset, Inc., EMORY UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTERInventors: Raymond F. Schinazi, Junxing Shi, Erik Gustafson, Joyce D. Fingeroth
-
Publication number: 20100160249Abstract: The use of squalenic acid or a derivative thereof in formulating at least one polar active principle with a molecular weight of 100 Da or more, in the form of nanoparticles, and pharmaceutical compositions thereof.Type: ApplicationFiled: March 4, 2010Publication date: June 24, 2010Applicants: Centre National De La Recherche Scientifique, Universite Paris-SudInventors: Patrick Couvreur, Barbara Stella, Luigi Cattel, Flavio Rocco, Jack-Michel Renoir, Véronique Rosilio
-
Patent number: 7741296Abstract: Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size of an established tumor) using acyclic nucleoside analogs has been disclosed.Type: GrantFiled: March 27, 2006Date of Patent: June 22, 2010Inventor: Igor E. Bondarev
-
Publication number: 20100151042Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of an influenza viral infection. In a preferred embodiment, a cysteamine compound and viral therapeutic are concurrently administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is concurrently administered with a viral therapeutic to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).Type: ApplicationFiled: May 27, 2008Publication date: June 17, 2010Inventors: Hao Yi Liang, Francis Chi, Qingfu Xu, Bill Piu Chan
-
Publication number: 20100152126Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: December 8, 2009Publication date: June 17, 2010Applicants: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Publication number: 20100151004Abstract: Methods for the treatment of disorders, including cancer, are described which include administering to a subject a DNA methylation inhibitor and an antineoplastic agent. Compositions containing a DNA methylation inhibitor and an antineoplastic agent, which are useful in treating disorders including cancer, are also described. Additionally, methods useful for developing a prognosis for or diagnosing a subject's development of resistance to treatment with a chemotherapeutic agent are described.Type: ApplicationFiled: March 7, 2008Publication date: June 17, 2010Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Debabrata Banerjee, Joseph R. Bertino, Rita Humeniuk, Prasun J. Mishra
-
Patent number: 7737128Abstract: The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder.Type: GrantFiled: June 10, 2005Date of Patent: June 15, 2010Assignee: The McLean Hospital CorporationInventor: Perry Renshaw
-
Publication number: 20100144665Abstract: The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, eg Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof (“uridine related compounds”). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods.Type: ApplicationFiled: February 16, 2010Publication date: June 10, 2010Applicant: MAGRAL LIMITEDInventor: Anthony William Linnane
-
Publication number: 20100143295Abstract: The present invention relates to new quinazoline inhibitors of EGFR tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 4, 2009Publication date: June 10, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100130440Abstract: Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus.Type: ApplicationFiled: May 18, 2009Publication date: May 27, 2010Inventors: Rakesh Kumar, Babita Agrawal, D. Lorne J. Tyrrell
-
Publication number: 20100130439Abstract: Modulators of error prone DNA polymerases are provided. Methods of inhibiting genomic mutation to inhibit the emergence of drug resistant target cells are also provided. Screening assays for identifying modulators of error prone DNA polymerases are provided.Type: ApplicationFiled: April 25, 2008Publication date: May 27, 2010Inventors: Floyd E. Romesberg, Daniel A. Bachovchin
-
Publication number: 20100129321Abstract: The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused thereby comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.Type: ApplicationFiled: December 6, 2006Publication date: May 27, 2010Applicant: BAYER HEALTHCARE LLCInventors: Olaf Weber, Bernd Riedl
-
Publication number: 20100124543Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.Type: ApplicationFiled: July 16, 2009Publication date: May 20, 2010Applicant: Vertex Pharmaceuticals IncorporatedInventors: Roger Dennis Tung, Michael Robin Hale, Christopher Todd Baker, Eric Steven Furfine, Istvan Kaldor, Wieslaw Mieczylaw Kazmierski, Andrew Spaltenstein
-
Publication number: 20100119580Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.Type: ApplicationFiled: January 19, 2010Publication date: May 13, 2010Applicant: pSivida Inc.Inventors: Hong Guo, Paul Ashton
-
Patent number: 7713948Abstract: The invention relates to the use of at least one overexpression inhibitor of DNA repair genes and oncogenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy.Type: GrantFiled: November 20, 2003Date of Patent: May 11, 2010Assignee: Resprotect GmbHInventors: Rudolf Fahrig, Joerg-Christian Heinrich, Georg Krupitza
-
Patent number: 7709449Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.Type: GrantFiled: July 10, 2007Date of Patent: May 4, 2010Assignee: Migenix, Inc.Inventors: Radhakrishnan P. Iyer, Yi Jin, Arlene Roland, Wenqiang Zhou
-
Patent number: 7709459Abstract: Pyrimidine nucleotide precursors including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.Type: GrantFiled: April 24, 2003Date of Patent: May 4, 2010Assignee: Wellstat Therapeutics CorporationInventors: Reid W. von Borstel, Michael K. Bamat, Bradley M. Hiltbrand
-
Patent number: 7704971Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.Type: GrantFiled: September 1, 2006Date of Patent: April 27, 2010Assignee: SmithKlineBeecham CorporationInventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
-
Patent number: 7700576Abstract: Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors, viz., Zidovudine, Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients. It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase inhibitor.Type: GrantFiled: August 8, 2006Date of Patent: April 20, 2010Assignee: Latvian Institute of Organic SynthesisInventors: Vija Klusha, Sergejs Isajevs, Jolanta Pupure, Juris Rumaks, Valentina Gordjushina, Immanuels Taivans, Ivars Kalvinsh
-
Publication number: 20100093655Abstract: The present invention relates to the use of riluzole or pharmaceutically acceptable salts of riluzole in the production of drugs for restoring and amplifying the immune function in the treatment of infectious diseases and cancers.Type: ApplicationFiled: December 28, 2007Publication date: April 15, 2010Inventor: Ammar Achour
-
Publication number: 20100087388Abstract: The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa, Streptococcal species, and Pneumocystis carinii).Type: ApplicationFiled: October 3, 2006Publication date: April 8, 2010Inventors: Lakshmi P. Kotra, Emil F. Pai
-
Patent number: 7691890Abstract: The present invention relates to anti-viral uses of leflunomide product, alone or in combination with other anti-viral agents, or in combination with a pyrimidine such as uridine.Type: GrantFiled: March 11, 1999Date of Patent: April 6, 2010Inventors: James W. Williams, Anita Chong, W. James Waldman
-
Patent number: 7691826Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.Type: GrantFiled: August 12, 2004Date of Patent: April 6, 2010Assignee: Lipoxen Technologies LimitedInventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
-
Publication number: 20100081627Abstract: Disclosed are polymeric compounds which are useful as prodrugs, comprising a chain of monomeric nucleosides, nucleoside analogs or abasic nucleosides, wherein at least one of the nucleosides or nucleoside analogs or a heterocyclic derivative thereof is pharmaceutically active and the nucleosides, nucleoside analogs or abasic nucleosides are linked by a phosphodiester group, a phosphorothioate group or an H—, alkyl or alkenyl phosphonate group.Type: ApplicationFiled: October 2, 2009Publication date: April 1, 2010Applicant: RELIABLE BIOPHARMACEUTICAL, INC.Inventors: UmaShanker Sampath, Joseph A. Toce, Sourena Nadji
-
Publication number: 20100075914Abstract: The present invention relates to methods for treating, killing, and/or inhibiting the growth of Herpes viruses in human subjects comprising topically administering to a human subject in need thereof a nanoemulsion composition having antiviral properties.Type: ApplicationFiled: April 17, 2009Publication date: March 25, 2010Inventors: Mary R. FLACK, Susan Marie CIOTTI, Tarek HAMOUDA, Joyce A. SUTCLIFFE, James R. Baker, JR.
-
Publication number: 20100075917Abstract: The invention relates to a pharmaceutical composition containing as an active ingredient at least one compound selected from the compounds of the formula (II), in which the S atom is bonded to the nucleoside carbon at T or to the nucleoside carbon at 3?, and from the compounds of the following formula (III): formulae in which B is a nucleotide natural or modified base, x is 0, 1 or 2, and R1 and R represent a carbonated group or a molecular hydrocarbon remnant that can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si, X where X is halogen. The invention also relates to pharmaceutically acceptable carrier.Type: ApplicationFiled: October 29, 2007Publication date: March 25, 2010Applicant: UNIVERSITE JOSEPH FOURIER (GRENOBLE 1)Inventors: Jean-Luc Decout, Beatrice Gerland, Jerome Desire, Michel Lepoivre, Jan Balzarini
-
Publication number: 20100048500Abstract: The present invention relates to novel compounds according to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: and the remaining variables as defined in the specification, and pharmaceutical compositions comprising the compounds. The compounds are useful interalia as anti-viral agents in viral therapy.Type: ApplicationFiled: August 17, 2009Publication date: February 25, 2010Inventors: Yung-chi Cheng, Hiromichi Tanaka, Masanori Baba
-
Publication number: 20100048504Abstract: Physical forms of beta-L-2?-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2?-deoxythymidine can be used in the manufacture of other forms of beta-L-2?-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.Type: ApplicationFiled: July 20, 2009Publication date: February 25, 2010Applicant: Novartis AGInventors: David Jonaitis, Richard Storer
-
Publication number: 20100041620Abstract: The invention provides methods and compositions for augmenting bioenergetic metabolism in the frontal brain involving administration of a cytidine-containing or uridine-containing compound to a human.Type: ApplicationFiled: August 14, 2009Publication date: February 18, 2010Inventors: Perry Renshaw, Deborah Yurgelun-Todd
-
Patent number: 7662361Abstract: The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing agent such as paclitaxel, and a telomerase inhibitory agent such as AZT. The invention also provides methods for identifying other agents with telomere damage-inducing activity and/or telomerase inhibitory activity (as well as and compositions having such activity), for use in the treatment of cancer.Type: GrantFiled: February 2, 2006Date of Patent: February 16, 2010Inventors: Jessie L.-S. Au, M. Guillaume Wientjes
-
Patent number: 7662798Abstract: 2? and 3?-Prodrugs of 1?, 2?, 3? or 4?-branched ?-D or ?-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: GrantFiled: June 27, 2003Date of Patent: February 16, 2010Assignees: Idenix Pharmaceuticals, Inc., University of Cagliari, Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Paola LaColla, Jean-Pierre Sommadossi, Gilles Gosselin
-
Publication number: 20100029580Abstract: The present invention relates to the constitutive activity of the Hedgehog pathway in non-small cell lung carcinoma (NSCLC). A method for diagnosing NSCLC by detecting the level of a component of the Hedgehog pathway is provided, as is a method for identifying subjects that will respond positively to treatment with a Hedgehog pathway antagonist. Methods for treating subjects with cancer or cancers resistant to Hedgehog pathway antagonists are also provided.Type: ApplicationFiled: April 12, 2006Publication date: February 4, 2010Inventors: David J. Robbins, Ziqiang Yuan, John A. Goetz
-
Publication number: 20100003213Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: September 16, 2009Publication date: January 7, 2010Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Publication number: 20090324741Abstract: An injectable polymer-lipid blend is provided. The blend may provide a localized drug delivery system for a pharmaceutically active agent. The blend may be prepared from a chitosan-based material, fatty acid and phospholipid. The chitosan-based material may be a water soluble chitosan derivative. The fatty acid may be a fatty acid or a fatty aldehyde, such as laurinaldehyde, having an acyl chain length of C8-C16. The rheological properties of the blend relates to the ratio of the components and to the acyl chain length of the fatty acid. The injectable system is well suited for the delayed release of pharmaceutically active agents in the treatment of cancer and other diseases requiring localized drug delivery.Type: ApplicationFiled: August 28, 2008Publication date: December 31, 2009Inventors: Christine ALLEN, Justin GRANT, Jaepyoung CHO, Patrick LIM SOO, Micheline PIQUETTE-MILLER
-
Patent number: 7638500Abstract: Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. wherein R, OR1, and R2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.Type: GrantFiled: April 10, 2007Date of Patent: December 29, 2009Assignee: University of North Carolina at WilmingtonInventors: Daniel G. Baden, William M. Abraham, Andrea J. Bourdelais, Sophie Michelliza
-
Patent number: 7638501Abstract: In accordance with the present invention, there are provided methods for the treatment of mitochondrial disorders. Invention methods include the administration of a pyrimidine-based nucleoside such as triacetyluridine, or the like. Also provided are methods of reducing or eliminating symptoms associated with mitochondrial disorders. Mitochondrial disorders particularly appropriate for treatment include those attributable to a deficiency of one or more pyrimidines.Type: GrantFiled: February 23, 2000Date of Patent: December 29, 2009Assignee: The Regents of the University of CaliforniaInventor: Robert K. Naviaux
-
Patent number: 7638502Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.Type: GrantFiled: December 4, 2006Date of Patent: December 29, 2009Assignees: Pharmasset, Inc., Beth Israel Deaconess Medical Center, Emory UniversityInventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
-
Publication number: 20090318380Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.Type: ApplicationFiled: November 14, 2008Publication date: December 24, 2009Applicant: PHARMASSET, INC.Inventors: MICHAEL JOSEPH SOFIA, JINFA DU
-
Patent number: 7635690Abstract: The present invention discloses a method for treating HIV that includes administering ?-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using ?-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. ?-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.Type: GrantFiled: October 3, 2006Date of Patent: December 22, 2009Assignee: Emory UniversityInventors: Raymond F. Schinazi, Jennifer L. Hammond, John W. Mellors, Dennis C. Liotta
-
Patent number: 7632821Abstract: The present invention provides ribonucleoside 2?,3?-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2?,3?-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection.Type: GrantFiled: August 4, 2006Date of Patent: December 15, 2009Assignee: Merck & Co., Inc.Inventors: Gabor Butora, Kenneth Alan Koeplinger, Malcolm MacCoss, Daniel R. McMasters, David B. Olsen, Lihu Yang
-
Publication number: 20090291908Abstract: This invention provides for a method of synergistically reducing viral load in a patient infected with a virus. The method comprises the oral co-administering an amount of thiophosphonoformic acid and an amount of a nucleoside or nucleotide reverse transcriptase inhibitor in a synergistic combination.Type: ApplicationFiled: March 6, 2006Publication date: November 26, 2009Applicant: Adventrix Pharmaceuticals, Inc.Inventors: Shani Waninger, Joan Robbins, Ramos Silvestri
-
Patent number: 7622458Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.Type: GrantFiled: November 15, 2004Date of Patent: November 24, 2009Assignee: Pharma Mar, S.A.U.Inventor: Mary Ellen Rybak
-
Publication number: 20090286755Abstract: To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. The invention provides a radiation therapy potentiator containing, as an effective ingredient, a uracil derivative represented by formula (1) (wherein R1 represents a halogen atom or a cyano group; and R2 represents a 4- to 8-membered heterocyclic group having 1 to 3 nitrogen atoms and optionally having as a substituent a lower alkyl group, an imino group, a hydroxyl group, a hydroxymethyl group, a methanesulfonyloxy group, or an amino group; an amidinothio group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group; a guanidino group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group or a cyano group; a lower alkylamidino group; or a 1-pyrrolidinylmethyl group) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 28, 2007Publication date: November 19, 2009Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Masakazu Fukushima